The collaboration between Predictive Oncology and Fujifilm is directly aimed at improving a critical aspect of biopharmaceutical production - the detection of bacterial endotoxins. By focusing on reducing protein interference, this partnership could lead to more accurate and reliable testing methods. This improvement in testing is likely to be well-received by the biopharmaceutical industry, potentially increasing the demand for Predictive Oncology's services. The direct involvement in enhancing drug safety and efficacy could positively impact POAI's market position and investor perception.